TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Researchers at Yale University target tuberculosis
May 5th, 2009
According to recent research published in the journal Drugs of the Future, "The tuberculosis (TB) epidemic constitutes a major global health threat. The steady emergence of Mycobacterium tuberculosis strains resistant to current anti-TB drugs, the therapeutic obstacles posited by coinfection with HIV and the cumbersome implementation of current treatment protocols all demand the development of new, fast-acting, effective compounds that shorten and simplify the treatment of TB." "TMC-207 (R-207910) is a novel diarylquinoline with a unique biological target: the F0 subunit of mycobacterial ATIP synthase. TMC-207 exhibits high in vitro activity against a wide range...
Source: TB & Outbreaks Week (2009-05-05)
|
